This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Factors to Note Ahead of Pilgrim's Pride's (PPC) Q1 Earnings
by Zacks Equity Research
Pilgrim's Pride's (PPC) first-quarter 2023 results are likely to be affected by cost-related hurdles.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $45.99, moving -1.01% from the previous trading session.
Factors to Note Ahead of Kimberly-Clark's (KMB) Q1 Earnings
by Zacks Equity Research
Kimberly-Clark's (KMB) first-quarter performance is likely to have witnessed gains from pricing, saving and key strategic efforts amid cost concerns and currency headwinds.
Altria (MO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Altria Group, Inc. (MO): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Altria (MO). This makes it worthwhile to examine what the stock has in store.
Philip Morris (PM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of 3.76% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Factors to Watch as Philip Morris (PM) Readies for Q1 Earnings
by Zacks Equity Research
Philip Morris' (PM) first-quarter results are likely to reflect gains from pricing and smoke-free products amid escalated costs and margin pressure.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $44.97, marking a +0.31% move from the previous day.
Altria (MO) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $44.43, marking a -0.04% move from the previous day.
Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVY
Factors to Drive Constellation Brands' (STZ) Earnings in Q4
by Zacks Equity Research
Constellation Brands' (STZ) Q4 results are expected to benefit from strength in the beer business, its premiumization strategy and growth of high-end Power Brands.
Zacks Industry Outlook Highlights Philip Morris International, Altria Group and Turning Point Brands
by Zacks Equity Research
Philip Morris International, Altria Group and Turning Point Brands have been highlighted in this Industry Outlook article.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $44.50 in the latest trading session, marking a -0.04% move from the prior day.
3 Tobacco Stocks Worth Watching Despite Industry Headwinds
by Vrishali Bagree
The Zacks Tobacco industry players are seeing low cigarette sales and commodity cost inflation. However, a focus on low-risk products and solid pricing bode well for Philip Morris (PM), Altria Group (MO) and Turning Point Brands (TPB).
Altria's (MO) Smoke-Free Products Aid Amid Low Cigarette Volume
by Zacks Equity Research
Altria (MO) has been benefiting from its Oral Tobacco Products and strong pricing power. However, soft volumes in the Smokeable Products segment are a concern.
Altria (MO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $43.97, marking a +1.17% move from the previous day.
Altria (MO) on Growth Track, Unveils 2028 Enterprise Goals
by Zacks Equity Research
Altria (MO) unveils 2028 Enterprise Goals, including corporate financial metrics and U.S. smoke-free portfolio goals. The company is building an impressive portfolio of smoke-free products.
Top Analyst Reports for Eli Lilly, Honeywell International & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Honeywell International Inc. (HON) and American Express Co. (AXP).
Here is What to Know Beyond Why Altria Group, Inc. (MO) is a Trending Stock
by Zacks Equity Research
Altria (MO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVY
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Altria (MO) closed at $46.20, marking a +0.28% move from the previous day.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $46.87 in the latest trading session, marking a +0.28% move from the prior day.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Altria (MO) Stock Moves -0.13%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $46.74 in the latest trading session, marking a -0.13% move from the prior day.
Is Trending Stock Altria Group, Inc. (MO) a Buy Now?
by Zacks Equity Research
Altria (MO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.